<DOC>
	<DOCNO>NCT00499811</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat treat patient metastatic unresectable solid tumor lymphoma liver dysfunction . ( close accrual 04/05/2010 ) Vorinostat may stop growth cancer cell block enzymes need cell growth . Vorinostat may different effect patient change liver function .</brief_summary>
	<brief_title>Vorinostat Treating Patients With Metastatic Unresectable Solid Tumors Lymphoma Liver Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine pharmacokinetic disposition vorinostat ( SAHA ) patient metastatic unresectable solid tumor lymphoma vary degree hepatic dysfunction . II . Establish maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) vorinostat group patient vary degree hepatic dysfunction ( mild , moderate , severe ) . SECONDARY OBJECTIVES : I . Document non-DLTs associate administration vorinostat patient hepatic dysfunction . II . Determine association Child-Pugh classification hepatic dysfunction observe toxicity , plasma pharmacokinetics , pharmacodynamics vorinostat administration . III . Document antitumor activity associate vorinostat treatment patient enrol study . OUTLINE : This parallel-group , dose-escalation study . Patients stratify accord level hepatic dysfunction ( normal v mild v moderate v severe ) . ( close accrual 04/05/2010 ) PART I : Vorinostat ( SAHA ) administer single oral dose day -6 patient . Blood sample obtain periodically day -6 pharmacokinetic study . PART II : One week later ( day 1 ) , first course oral vorinostat initiate continuous daily oral regimen . Each treatment course consist 21 day therapy . Treatment continue absence disease progression unacceptable toxicity . Dose escalation proceed within hepatic dysfunction group ( except normal group ) . Only dose-limiting toxicity ( DLTs ) occur first cycle treatment use guide dose escalation . The maximum tolerated dose ( MTD ) high dose one instance DLT observe ( among 6 patient treat ) . Once MTD determine give hepatic dysfunction group , maximum 12 patient accrue dose level . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histologically cytologically confirm solid malignancy lymphoma metastatic unresectable Patients liver mass , elevate αfetoprotein level ( ≥ 500 ng/mL ) , positive serology hepatitis consistent diagnosis hepatocellular carcinoma eligible without need pathologic confirmation diagnosis Standard curative palliative measure exist longer effective Patients receive prior therapy malignancy also eligible ineligible standard therapy due hepatic dysfunction Patients abnormal liver function eligible No distinction make liver dysfunction due metastasis liver dysfunction due cause Patients biliary obstruction shunt place eligible , provide shunt place least 10 day prior first dose vorinostat ( SAHA ) liver function stabilize Two measurement least 2 day apart put patient hepatic dysfunction stratum accept evidence stable hepatic function No evidence biliary sepsis Patients glioma brain metastasis require corticosteroids anticonvulsant must stable dose corticosteroid seizure free 1 month prior study enrollment Patients know brain metastasis brain irradiation ( whole brain gamma knife ) 4 week start protocol treatment Patients unstable untreated ( nonirradiated ) brain metastasis exclude ECOG performance status ≤ 2 ( Karnofsky ≥ 60 % ) Life expectancy &gt; 3 month Absolute neutrophil count &gt; 1,500/mm^3 Platelets ≥ 100,000/mm^3 Creatinine within normal institutional limit OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Fertile patient must use effective contraception HIVpositive patient without AIDSdefining diagnosis receive agent potential pharmacokinetic interaction vorinostat may eligible Able take oral medication continuous basis No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement No active hemolysis More 3 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) recover Patients treated agent persist body longer 4 6 week ( suramin ) ineligible elimination period agent More 14 day since prior major surgery No prior vorinostat At least 2 week since prior valproic acid histone deacetylase inhibitor More 4 week since prior investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent therapy enzymeinducing anticonvulsant No concurrent prophylactic granulocyte growth factor first cycle therapy No concurrent investigational commercial agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>